Out-licensing: Phytohealth Corporation: PHN032 - Adjuvant For Oral/nasal Vaccines Against Influenza And Bird Influenza

Out-licensing
View

Phytohealth Corporation: PHN032 - Adjuvant for oral/nasal vaccines against influenza and bird influenza

Patented technology regarding a superior adjuvant with the active substance polysaccharide for oral/nasal vaccines against influenza and bird influenza, targeted to the aging population.

Full description

PHN032 is a fraction of polysaccharides extracted from a Chinese herb. Pharmacology and mechanism of action: Studies show that PHN032, as vaccine adjuvant, largely enhances mucosal immunization for IgA production as well as systematic immunization for both IgM and IgG production. Competitive niches: • Benefits the aging population as weak response to immunization is of concern. • Induces both mucosal and systematic immune responses. • The elicited mucosal immune response serves as the first line defense against foreign pathogens prior to the systematic responses. • Oral or nasal vaccines are easier to use than injectible vaccines. • Safer than cholera toxin subunit for similar applications. • Can be applied to other vaccines, and can be used in child populations.

Development status

Early Stage

Patent information

The first US patent (patent number: 6,998,262 B2) of PHN032 has been granted as of June 2005 and more relevant patents (application number: 11/093,970) have been and will continue to be filed.

Type of business relationship sought

Licensing or partnering.

Licensing contact

Dr. T.S. Jiang
Chief Executive Officer
PhytoHealth Corporation

Contact directly

Company details

BiotechEast Co., Ltd. (Technology Partner)

BiotechEast is a one-stop, full-service marketing consultancy for those looking to take advantage of the dynamic opportunities in Taiwan's burgeoning life science industry.

View profile

Visit website

Related reports

Are you looking for reports related to this particular subject. Our Reports section is the best place to start.

Compositions and Methods for Increasing Recombinant Protein Yields Through the Modification of Cellular Properties

Universally Applicable Technology for Inactivation of Enveloped Viruses and Other Pathogenic Microorganisms for Vaccine Development

ImmLab's primary product: A Therapeutic Staphylococcal Lysate (SL) as described in our patent 6,929,798 and 7,329,409 granted by the U.S. Patent and Trademark Office

New detoxification method.

Related categories

Industry sector: Drug delivery / Nasal / Aerosol; Research tools / Antibodies; Research tools / Antigens; Drug delivery / Oral solid / Capsule; Drug delivery / Oral solid / Tablet / Freeze-dried; Research tools / Mouse models; Pharmaceutical / Nutrition; Biotechnology / Other; Pharmaceutical / Personal Care; Pharmaceutical; Academic/Research / Pharmaceutical; Drug delivery / Topical / Dermatological / Spray
Therapeutic target: Infectious diseases / Treatments / Antibodies; Infectious diseases / Diseases / Cholera; Immune related disorders; Immune related disorders / Immunostimulation; Infectious diseases / Diseases / Infection, bacterial(other); Infectious diseases / Diseases / Infection, viral (other); Infectious diseases / Diseases / Infectious disease (other); Infectious diseases / Diseases / Influenza; Infectious diseases / Diseases / Streptococcal infections; Infectious diseases / Treatments / Vaccine; Oncology / Treatments / Vaccines

Products:	Partnering Search	Company Profiling	Deal Negotiation	PL Intelligence	Reports	Comparision
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
Jobs:	Pharmaceutical jobs	Browse jobs	Search for jobs	Create your CV	Employer profiles	Post your jobs
Forums:	Talk to an expert	Industry Gossip	Business Development	What's new	Reports	Services
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search
Articles:	Business Development	Technologies	Events	Legal and regulatory	Therapeutic
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Press releases
About us:	Our Audience	Case Studies	Newsletter	Careers	FAQ	Contact us